STEPHEN DILLY

Stephen G. Dilly is currently CEO of Codexis Inc. During a 35-year industry career, he has been associated with the development, approval and launch of more than 20 novel medications across multiple therapeutic areas.

Stephen was CEO of Sierra Oncology from May 2020 until August 2022. During his tenure, Sierra Oncology successfully executed the Phase 3 MOMENTUM trial in myelofibrosis patients with anemia in 160 centers across 16 countries in Europe, North America and Asia despite the challenges of the COVID pandemic. Positive topline data release in early 2022 was followed by an oversubscribed $150 million follow-on offering, NDA filing, and then acquisition of the Company by GSK for $1.9 billion in July 2022.

Previously, Stephen served as CEO of Aimmune therapeutics and led the development of Palforzia, the first FDA approved treatment for peanut allergy. Aimmune Therapeutics was acquired by Nestle Health Science for $2.6 billion.

Stephen also held executive roles at Genentech, Chiron and SmithKline Beecham.

Stephen believes passionately that the key determinants of success are clarity of purpose and focus.  Often the role of the leader is to set a clear direction, challenge the organization to go outside the comfort zone and to remove the distractions. Breakthroughs are almost always the product of teamwork galvanized by a compelling mission.